跳至主要内容
临床试验/NCT01503957
NCT01503957已完成3 期

Double-blind, Randomized, Placebo-controlled, Crossover Clinical Investigation to Evaluate Safety and Efficacy of Nasya in Reducing Symptoms of Allergic Rhinitis When Applied Before Allergen Challenge

InQpharm Group1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2012年1月1日最近更新:
适应症
干预措施

试验速览

阶段
3 期
状态
已完成
入组人数
20
试验地点
1
主要终点
Difference in Total Nasal Symptom Score

研究概览

简要总结

The purpose of this study is to evaluate safety and efficacy of Nasya in reducing symptoms of persistent allergic rhinitis when applied before allergen challenge.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Prevention
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者
否

入选标准

  • •History of persistent allergic rhinitis due to house dust mite allergy ≥ 2 years
  • •Written informed consent

排除标准

  • •Clinically significant disease that could interfere with the evaluation of study medication
  • •Participation in other studies within the last 4 weeks / during the study

研究组 & 干预措施

Saline solution

Placebo Comparator

Nasal spray

干预措施: Saline solution (Device)

Nasya

Experimental

Thixotropic nasal spray suspension

干预措施: Nasya (Device)

结局指标

主要结局

Difference in Total Nasal Symptom Score

时间窗: 75 minutes

次要结局

  • Difference in Total Nasal Symptom Score(Up to 240 minutes)
  • Difference in Total Ocular Symptom Score(Up to 240 minutes)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验